Current misconception 3: That subgroup-specific trial mortality results often provide a good basis for individualising patient care

British Journal of Cancer

Volumn 104, Issue 7, 2011, Pages 1057-1058

  Peto, R ^a  

^a CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

ACUTE HEART INFARCTION; ADVERSE OUTCOME; BREAST CANCER; DRUG CONTRAINDICATION; EDITORIAL; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; MORTALITY; MYSTICISM; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION; SURVIVAL RATE;

ASPIRIN; CLINICAL TRIALS AS TOPIC; HUMANS; INDIVIDUALIZED MEDICINE; MYOCARDIAL INFARCTION;

EID: 79953191165     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.79     Document Type: Editorial

References (4)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005a) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005b) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366: 2087-2106
3. Fibrinolytic Therapy Trialists' Collaborative Group (FTT) (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343: 311-322
4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 332: 349-360